J&J (JNJ) Faces $8M Verdict Over Talc Case; Stock Still Gains 4.66% YTD
Johnson & Johnson (NYSE:JNJ) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, Dean Omar Branham Shirley, LLP, a Dallas, Texas-based law firm, announced an $8 million verdict against Johnson & Johnson in Suffolk County, Massachusetts. The verdict was awarded to Janice Paluzzi, an 84-year-old Massachusetts woman who developed mesothelioma, a rare and aggressive cancer linked to asbestos exposure.
Copyright: moovstock / 123RF Stock Photo
According to the jury, the plaintiff's illness arose from her decades-long use of Johnson & Johnson's talcum powder products. The jury found that J&J's talcum powder products contained asbestos and that a design defect in these products substantially contributed to Ms. Paluzzi's mesothelioma. They also found Johnson & Johnson negligent in the design of the powder and that this negligence substantially contributed to her illness. As a remedy, the jury awarded Ms. Paluzzi $8 million: $5 million for past pain and suffering and $3 million for future pain and suffering.
Despite the unfavorable ruling, Johnson & Johnson's stock is up 4.66% year to date as of June 19.
Johnson & Johnson (NYSE:JNJ) is a global healthcare company. It develops and sells pharmaceuticals, medical devices, and consumer health products. It operates through two major divisions, pharmaceutical and MedTech. Some of its key pharmaceutical products include Darzalex, Stelara, and Tremfya.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Biotech Stocks Screaming a Buy and 13 Best Software Stocks to Buy Now.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
31 minutes ago
- Business Insider
‘Time to Jump In,' Says Analyst as He Upgrades Rating and PT on AMD Stock
Semiconductor giant Advanced Micro Devices (AMD) is starting to gain traction in the AI race, after earlier concerns about lagging Nvidia (NVDA). The stock is down 19% over the past year but is up more than 7% year-to-date. In a new update, Melius Research analyst Ben Reitzes upgraded the stock to Buy from Hold and raised the 12-month price target to $175.00 from $110.00, suggesting an impressive 35% upside from current levels. He believes the company's position has improved meaningfully in the AI space since the start of the year. Confident Investing Starts Here: Analyst Sees AI Upside Still Not Priced In According to Reitzes, AMD has moved past the early rebound phase and is now 'in the middle' of a broader rally, with further upside expected. While shares have seen big swings—rising to $211 last year before falling below $80 in 2025—he believes that recent progress isn't yet fully reflected in the price. One key reason behind this view is the growing demand for AMD's AI chips. The analyst pointed to strong interest from cloud providers and government-backed firms in AMD's MI300 and MI350 chips—both built for AI tasks. The upcoming MI400 line is also drawing early attention. He believes AI inferencing is turning out to be 'much bigger' than expected. With stronger memory and better software, AMD's chips are becoming more attractive to high-end buyers. The analyst also pointed to AMD's partnerships with Amazon (AMZN), Meta (META), OpenAI, and Saudi-based AI group HUMAIN. It's important to highlight that AMD and HUMAIN are investing up to $10 billion in data center projects across the Middle East. Melius believes this could drive major gains in the region, where AMD's market share may surpass its global share. Other Segments Show Signs of Strength While AI remains the top driver, Reitzes also noted signs of strength in AMD's PC business, due to higher average selling prices and modest share gains from Intel (INTC). These gains could help buffer AMD if Nvidia eventually enters the PC CPU market. Looking ahead, he also expects continued growth in AMD's server chip business. New products like the 'Venice' CPU and the 'Helios' rack-scale platform could help boost its presence in large data centers. Given these tailwinds, the firm has raised its earnings estimates through 2027. It now expects EPS to reach $3.88 this year, rising to $5.77 in 2026 and $7.08 in 2027. The analyst adds that if AMD captures more than 5% of the global AI chip market, the upside could be even higher. Is AMD Stock a Buy or Sell Now? To summarize, Wall Street is cautiously optimistic on Advanced Micro Devices stock, with a Moderate Buy consensus rating based on 22 Buys and 10 Holds. The average AMD stock price target of $132.17 indicates a modest upside potential of 2% from current levels.
Business Upturn
41 minutes ago
- Business Upturn
Hims & Hers Health, Inc. Shareholders Who Lost Money on Their Investment are Encouraged to Contact Johnson Fistel about the Class Action Investigation
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) regarding possible violations of federal securities laws. Investors who purchased Hims & Hers securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the company and its executives. What if I purchased Hims & Hers securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your losses, follow the link provided: For more information, contact James Baker at (619) 814-4471, [email protected] or [email protected]. On June 23, 2025, Novo Nordisk terminated its collaboration with Hims & Hers Health, citing serious concerns over the company's sale of compounded medications marketed as personalized treatments. According to Novo Nordisk, Hims allegedly skirted regulations by mass-distributing semaglutide-based drugs that may contain unauthorized foreign substances, raising significant safety red flags. This development has prompted increased scrutiny of Hims' business practices and legal compliance. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Yahoo
44 minutes ago
- Yahoo
Earnings To Watch: Lindsay (LNN) Reports Q2 Results Tomorrow
Agricultural and farm machinery company Lindsay (NYSE:LNN) will be announcing earnings results this Thursday morning. Here's what investors should know. Lindsay beat analysts' revenue expectations by 4% last quarter, reporting revenues of $187.1 million, up 23.5% year on year. It was an incredible quarter for the company, with a solid beat of analysts' organic revenue estimates and an impressive beat of analysts' EPS estimates. Is Lindsay a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Lindsay's revenue to grow 16.4% year on year to $162 million, a reversal from the 15.4% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.41 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Lindsay has missed Wall Street's revenue estimates four times over the last two years. With Lindsay being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for heavy machinery stocks. However, there has been positive investor sentiment in the segment, with share prices up 2.9% on average over the last month. Lindsay is down 1.1% during the same time and is heading into earnings with an average analyst price target of $139 (compared to the current share price of $138.22). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
